Contents Issue 108 • July 2021 In association with Blood plasma gets a green light in the UK After a 20-year ban, the UK life sciences sector has been given the go-head to produce blood plasma domestically once more IN DEPTH A history of malaria treatment Comment A new day for Alzheimer’s drugs Briefing Industry news Pharma industry briefing Covid-19 briefing Comment A new day for Alzheimer’s disease treatment after FDA approval Covid-19 vaccine inequity: the debate over patent waivers intensifies Covid-19 vaccine efficacy in adolescents Pharmacovigilance for biotechs In Depth Malaria vaccines through the ages Tightening the rules on pharma M&A The fishy business of shark squalene Can pharma reduce surgical scarring? Blood plasma production: OK for the UK? Can pharma keep up with mental health? In Data Inside the deal Deals analysis Market data 02/24/2024 03:28:44
Comment
A new day for Alzheimer’s drugs